32 / 33
Some take home messages
•
PEMBROLIZUMAB IS THE SOC in 1L NSCLC…PD-L1>=50%
•
New combinations of IO are too close…
•
Better Biomarkers: IT
´
S AN URGENT ISSUE
–
PD-L1 IHC plus…
–
Economical toxicity…
•
Don
´
t forget safety issues